2001, Number 1
<< Back Next >>
Rev Biomed 2001; 12 (1)
V Simposio de Actualización: SIDA 2000.
Góngora-Biachi RA, Valadez-González N, Castro-Sansores C, Guerrero-Flores A, Vera-Gamboa L
Language: Spanish
References: 337
Page: 47-62
PDF size: 67.87 Kb.
Text Extraction
No abstract
REFERENCES
TENDENCIAS EPIDEMIOLÓGICAS ACTUALES
DEL SIDA EN LA PENINSULA DE YUCATÁN.
1.- Góngora-Biachi RA, González-Martínez P. La dinámica
epidemiológica de la infección por el VIH-1 en Yucatán
(1983-1989). Rev Biomed 1990; 1:53-60.
2.- Góngora-Biachi RA. González-Martínez P. Reyes-Pino
A. Lara-Perera D. López-Peraza A. Medina-Escobedo G.
Prevalencia de anticuerpos contra el virus de la
Inmunodeficiencia Humana y su expresión clínico en un
grupo de homosexuales del sexo masculino de Mérida,
Yucatán. Salud Pública Mex 1987; 29:474-80.
3.- Magis-Rodríguez C, Bravo-García E, Anaya-López L,
Uribe-Zúñiga P. La situación del SIDA en México a finales
de 1998. SIDA-ETS 1998; 4:143-55.
4.- Góngora-Biachi RA, Arcila-Herrera H, González-
Martínez P, Franco-Monsreal J, Puerto-Manzano FI,
Martínez-Reynoso A, et al. Anticuerpos contra el virus de
Inmunodeficiencia Humana en una población homosexual
masculina Salud Pública Mex 1990; 32: 15-20.
5.- Góngora-Biachi RA, González-Martínez P. Anticuerpos
contra el Virus de Inmunodeficiencia humana (VIH) en una
población de prostitutas de Mérida, Yucatán, México. Rev
Invest Clin 1987; 39:305-6.
6.- Gongora-Biachi RA, Pavia-Ruz N, González-Martinez
P, Puerto FI. Female prostitution and HIV infection in
Yucatan Mexico. Fourth RCMI International AIDS
Symposium. San Juan , Puerto Rico. November 3-4, 1994.
7.- Góngora-Biachi RA, González-Martínez P, Puerto FI,
Sosa-Muñoz J, Duarte-Zapata L, Bastarrachea-Ortiz J, et
al. A low prevalence of HTLV-I/II infection among eight
population groups from Merida, Yucatan, Mexico. J Acquir
Immun Defic Synd 1992; 104-6.
8.- Góngora-Biachi RA, González-Martínez P, Castro-
Sansores C, Pavía-Ruz N, Rudolph DL, Lal RB. Human T
Lymphotropic Virus Type II (HTLV-II) infection among
female prostitutes in Yucatan, Mexico. Am J Med Sci 1993;
9.- Góngora-Biachi RA, González-Martínez P, Puerto FI,
Alvarez-Moguel R. Prevalencia de infección por retrovirus
(VIH-1 y HTLV-I) en donantes de sangre del Estado de
Yucatán, México. Sangre 1990; 35:489.
10.- González-Martínez P, Castro-Sansores C, Vivas-Rosel
M de la L, Góngora-Biachi RA. Infección por el virus
linfortrópico de células T humanas tipo I/II en pacientes
politrasnfundidos en el estado de Yucatán, México. Sangre
11.- Pavía-Ruz N. The women and AIDS. Rev Biomed 1994;
5:176-9.12.- Rico B, Liguori AL. Mujeres y VIH/SIDA: reflexiones
sobre la situación actual y algunos retos legislativos. SIDAETS
13.- Góngora-Biachi RA. González-Martínez P. Puerto-
Manzano FI. Franco-Monsreal J Transmisión heterosexual
del virus de la Inmunodeficiencia Humana tipo 1, En un
grupo de parejas residentes de la península de Yucatán. Rev
Invest Clin 1991; 43:128-32.
14.- Góngora-Biachi RA. González-Martínez P. Madera-
Rivas R. Puerto FI. Franco-Monsreal J. Ceh-Gómez E.
Infección por el virus de leucemia tipo 1 de células T
Humanas (HTLV-1) y el virus de la Inmunodeficiencia
Humana tipo 1 (VIH-1) en prostitutas residentes en la ciudad
de Mérida, Yucatán. Sangre 1991; 36: 158.
15.- Castro-Sansores CJ, Pavía-Ruz N, Lara-Perera D,
Alonzo-Salomón G, Góngora-Biachi RA. La detección de
anticuerpos contra el VIH como evaluación prenupcial. Rev
GRUPOS Y SUBTIPOS DEL VIRUS DE LA
INMUNODEFICIENCIA HUMANA TIPO 1.
1.- Hu D, Dondero TJ, Mastro TD and Gayle HD. 1998.
Global and molecular epidemiology of HIV. En Wormser
GP, ed. AIDS and other manifestations of HIV infection.
Philadelphia.:Lippincott-Raven Publishers; 1998.p.27-40.
2.- Myers GB, Korber B, Smith R, Pavlakis G, . Human
Retrovirus and AIDS –1996, a compilation of nucleic acids
and amino acid sequences. Los Alamos:Los Alamos National
3.- Gao F, Robertson DL, Carruthers CD, Morrison SG, Jian
B, Chen Y. A comprehensive panel of near-full length clones
and reference sequences for non-subtype B isolates of human
immunodeficiency virus type 1. J Virol 1998; 72:5680-98.
4.- Gürtler LG, Zekeng L, Tsague JM, Von Brunn A, Ze
EA, Eberle J, et al. HIV-1 subtype O: epidemiology,
pathogenesis, diagnosis, and perspectives of the evolution
of HIV. Arch Virol. 1996; 11(Suppl):195-202.
5.- Carr JK, Salminen MO, Albert J, Sanders-Buell E, Gotte
D, Birx L. Full genome sequences of human
immunodeficiency virus type 1 subtypes G and A/G
intersubtype recombinants. Virology. 1998; 247:22-31.
6.- Carr JK, Salminen MO, Koch C, Gotte D, Artenstein
AW, Hegerich PA. Full-length sequence and mosaic structure
of a human immunodeficiency virus type 1 isolate from
Thailand. J Virol. 1996; 70:5935-43.
MARCADORES GENETICOS DE PROGRESION Y
NO PROGRESION DE LA INFECCION POR EL VIH.
1.-D´Souza MP, Harden VA. Chemokines and HIV-1 second
receptors. Nat Med 1996; 2:1293-300.
2.- McNicholl JM, Smith DK, Qari SH, Hodge T. Host genes
and HIV: the role of the chemokine receptor gene CCR5
and its allele (delta32 CCR5). Emerg Infect Dis 1997; 3:261-
3.- O´Brien SJ, Dean M. In search of AIDS-resistance genes.
Sci. Amer 199; 277:44-51.
4.- Dean M, Carrington M, Winkler C, Huttley GA, Smith
MW, Allikmets R, et al. Genetic restriction of HIV-1
infection and progression to AIDS by a deletion allele of the
CKR5 structural gene. Science 1996; 273:1856-62.
5.- Dean M, Jacobson LP, McFarlane G, Margolick JB,
Jenkins FJ, Howard OM, et al. Reduced risk of AIDS
lymphoma in individuals heterozygous for the CCR5-delta32
mutation. Cancer Res 1999; 59:3561-4.
6.- Martin MP, Carrington M, Dean M, O’Brien SJ,
Sheppard HW, Wegner SA. CXCR4 polymorphisms and
HIV-1 pathogenesis. J AIDS 1998; 19:430.
7.- Smith MW, Dean M, Carrington M, Winkler C, Huttley
GA, Lomb DA. Contrasting genetic influence of CCR2 and
CCR5 receptor gene variants on HIV-1 infection and disease
progression. Science 1997; 277:959-65.
8.- Winkler C, Modi W, Smith MW, Nelson GW, Wu X,
Carrington M. Genetic restriction of AIDS pathogenesis by
an SDF-1 chemokine gene variant. Science 1998; 279:389-
9.- Carrington M, Nelson G, Martin MP, Kissner T, Vlahov
D, Goedert JJ. HLA and HIV-1: Heterozygote advantage and
B*35-Cw*04 disadvantage. Science 1999; 283:1748-52
10.- O’Brien SJ. Human Genetic Factors that impact HIV
infection and progression. /medscape/HIV/Annual Update/
2000/mha.updat.../pnt-mha05.obrien.htm
11.- Mellado M, Rodriguez–Frade JM, Vila-Coro AJ, de Ana
AM, Martinez AC. Chemokine control of HIV-1 infection.
12.- Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis
I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1
is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature
13.- Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier
JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-
1 is the ligand for LESTR/fusin and prevents infection by
T-cell-line adapted HIV-1. Nature. 1996; 382:833-5.
14.- Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo
RC, Lusso P. Identification of RANTES, MIP-1b as the major
HIV-suppressive factors produced by CD8+ T cells. Science
15.- Alkhatib G, Combadiere C, Broder CC, Feng Y,
Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES,
MIP-1a MIP-1b receptor as a fusion cofactor for macrophagetropic
HIV-1. Science1996; 272:1955-8.
16.-Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath
PD, et al. The beta chemokine receptors CCR3 and CCR5
facilitate infection by primary HIV-1 isolates. Cell. 1996;
17.- McKnight A, Wilkinson D, Simmons G, Talbot S,
Picard L, Ahuja M, et al. Inhibition of human
immunodeficiency virus fusion by a monoclonal antibody
to a coreceptor (CXCR4) is both cell type and virus strain
dependent. J Virol 1997; 71:1692-6.
18.- Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB,
Sullivan N, et al. CCR5 levels and expression pattern
correlate with infectability by macrophage-tropic HIV-1, in
vitro. J Exp Med 1997; 185:1681-91
19.- Wu L, Larosa G, Kassam N, Gordon CJ, Heath H,
Ruffing N, et al. Interaction of chemokine receptor CCR5
with the ligands: multiple domains for HIV-1 gp 120 binding
and a single domain for chemokine binding, Cell 1997;
20.- He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner
S, et al. CCR3 and CCR5 are co-receptors for HIV-1
infection of microglia. Nature 1997; 385:645-9.
21.- Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S,
Ritchey DW, et al. Differential regulation of HIV-1 fusion
cofactor expression by CD28 co-stimulation of CD4+ T cells.
Science 1997; 276:273-6 .
22.- Goila R, Banerjea AC. Sequence specific cleavage of
the HIV-1 coreceptor CCR5 gene by a hammer-head
ribozyme and a DNA-enzyme: inhibition of the coreceptor
function by DNA-enzyme. FEBS Lett 1998; 436:233-8.
23.- Chen JD, Bai X, Yang AG, Cong Y, Chen SY.
Inactivation of HIV-1 chemokine co-receptor CXCR4 by a
novel intrakine strategy. Nature Med 1997; 3:1110-6.
24.- Yang AG, Bai X, Huang XF, Yao C, Chen S. Phenotypic
knockout of HIV type 1 chemokine coreceptor CCR5 by
intrakines as potential approach for HIV-1 infection. Proc
Natl Acad Sci USA 1997; 94:11567-72.
SÍNDROME DE LIPODISTROFIA Y TRASTORNOS
METABÓLICOS ASOCIADOS A LA INFECCIÓN
1.- Dong KL, Bausserman LL, Flynn MM. Changes in body
habitus and serum lipid abnormalities in HIV-positive
women on highly active antiretroviral therapy (HAART). J
Acquir Immune Defic Syndr Hum Retrovirol 1991; 21: 107-
2.- Carr A, Samaras K, Burton S. A Syndrome of peripheral
lipodystrophy, hyperlipidaemia and insulin resistance in
patients receiving HIV proteases inhibitors. AIDS 1998; 12:
3.- Engelson EE, Kotler DP, Tan YX, Wang J, Pierson RN,
Heymsfield SB. Fat distribution in HIV-infected patients
reporting truncal enlargement quantified by whole-body
magnetic resonance imaging. Am J Clin Nutr 1999; 69:
4.- Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M,
Chernoff DN, et al. Hyperlipidaemia and insulin resitance
are induced by protease inhibitors independent of changes
in body composition in patients with HIV infection. J Acquir
Immune Defic Sindr Hum Retrovirol 2000; 23: 35-43.
5.- Carr A, Samaras K, Thorisdottir A, Kaufmann GR,
Chsiholm DJ, Cooper DA. Diagnosis, prediction, and natural
course of HIV-1 protease-inhibitor-associated lipodystrophy,
hyperlipidaemia and diabetes mellitus: a cohort study. Lancet
6.- Carr A. HIV protease inhibitor-induced lipodystrophy
syndrome. AIDS Rev 1999; 1: 29-36.
7.- Kakuda TN. Pharmacology of nucleoside and nucleoside
transcriptase inhibitor-induced mitochondrial toxicity. Clin
8.- Polsky B. Update on Metabolic and Morphologic
Abnormalities in HIV Infection. HIV / AIDS Treatment
Updates (Serial Online) September 1999. Available from:
URL:http://HIV.medscape.com/Medscape/HIV/
TreatmentUpdate/1999/tu11/tu11-01.html.
QUIMIOPROFILAXIS CONTRA EL VIRUS DE LA
INMUNODEFICIENCIA HUMANA (VIH) LUEGO DE
EXPOSICIÓN LABORAL EN TRABAJADORES DE
1.- Weiss SH, Saxinger WC, Rechtman D, Grieco MH,
Nadler J, Holman S, et al. HTLV-III infection among health
care workers: association with needle stick injuries. JAMA
2.- McCray E. For the cooperative needlestick surveillance
group. Occupational risk of the adquired immunodeficiency
syndrome among health care workers. N Engl J Med 1986;
3.- Center For Disease Control. Acquired Immunodeficiency
Syndrome: precautions for health care workers and allied
professionals. MMWR 1983; 32:450-1.
4.- Center For Disease Control. Recommendations for
prevention of HIV transmission in health care setting.
5.- Center For Disease Control. Recommendations for
prevention of HIV transmission in health care settings.
6.- Garner JS, Guideline for isolation precautions in
hospitals. The Hospital Infection Control Practices advisory
Committe. Infec Control Hosp Epidemiol 1996; 17: 53-80.
7.- Mitsuya H, Weinhold KJ, Furman PA, St Clair MH,
Lerhman SN, Gallo RC, et al. 3´azido-3´deoxithymidine
(BW-A509U): an antiviral agent that inhibits the infectivity
and cytopathic effect to human T lymphotropic virus type
III lymphadenopathy associated virus in vitro. Proc Natl
Acad Sci 1985; 82:7096-100.
8.- Herderson DK, Beekmann SE, Gerberding JL. Post
exposure antiviral chemoprophylaxis following occupational
exposure to the human immunodeficiency virus. In: de Vita
VT, Hellman S, Rosemberg SA, Eds. AIDS Update: AIDS
etiology, diagnosis treatment and prevention. Philadelphia:
JB Lippincott; 1990. p. 1-8.
9.- Henderson DK, Gerberding JL. Prophilactic zidovudine
after occupational exposure to the human
immunodeficiency virus: an interim analysis. J Infec
10.- Para MF. Use of zidovudine following occupational
exposure to human immunodeficiency virus. Clin Infect
11.- Robinson JR. Argument against the chemoprophilactic
use of zidovudine following of occupational exposure to
the human immunodeficiency virus. Clin Infect Dis 1993;
12.- Tamin J, Menzies D, Gilbert D, Parker G, Hui E.
Zidovudine after occupational exposure to HIV-1. current
status and prospects for the future. Am J Med 1991; 91:
TRATAMIENTO DE LA MUJER EMBARAZADA Y
PROFILAXIS PARA LA TRANSMISION MATERNOFETAL.
1.- Report on the Global HIV/AIDS epidemic. Available
from:hhtp://www.unaids.org/epidemic_update/
report_dec00/index_dec.html full. Noviembre 2000.
2.- Levine AM. Mother-to-child HIV transmission and its
prevention. Available from Mgmt/CM.v16/public/index-
3.- Ortiz-Ibarra FJ. Prevención de la transmisión perinatal
del virus de la inmunodeficiencia humana. La luz al final
del túnel. Enferm Infec Microbiol 1999:19:263-5.
4.- Connor EM, Sperling RS, Gelber R, Kiselev P, Scott
G, O'Sullivan MJ, et al. Reduction of maternal-infant
transmssion of human immunodeficiency virus type1 with
zidovudine treatment. N Engl J Med 1994; 331:1173-80.
5.- Cooper RE, Nugent RP, Diaz C, Pitt J, Hanson C, Kalish
LA, et al. After AIDS Clinical Trial 076: the changing
pattern o zidovudine use during pregnancy, and the
subsequuent reduction in vertical transmission of human
immunodeficiency virus in a cohort of infected women and
their infants. J Infect Dis 1996: 174:1207-11.
6.- Mofenson LM, Fowler MG. Interruption of maternofetal
transmission. AIDS 1999; 13(Suppl A):S205-14.
7.- Riley LE, Greene MF. Elective cesarean delivery ti
reduce the transmission of HIV. N Engl J Med 1999;
8.- Stratton P, Tuomala RE, Abboud R, Rodriguez E, Rich
K, Pitt J, et al.. Obstetric and newborn outcomes in a cohort
of HIV-infected pregnant women: A report of the women
and infants transmission Study. J Acquir Immune Defic
Synd Hum Retrovirol 1999; 20:179-86.
9.- García P, Kalish L, Pitt J, Minkoff H, Quinn TC, Burchet
S, et al. Maternal levels of plasma human
inmmunodeficiency virus type 1 RNA and the risk of
perinatal tarnsmission. N Engl J Med 1999; 341:394-402.
10.- Murray MC, Embree JE, Ramdahin SG, Anzala AO,
Njenga S, Plummer FA. J Infect Dis 2000; 181: 746-9.
11.- Mangano A, Kopka J, Batalla M, Bologna R, Sen L.
Protective Effect of CCR2-641 and not of CCR5- 32 SDF-
3 A in pediatric HIV-1 infection. J Acquir Immune Defic
Synd Hum Retrovirol 2000; 23:52-7.
12.- Centers for Disease Control and Prevention.
Administration to zidovudine during late pregnancy and
delivery to prevent perinatal transmission-Thailand 1996-
1998. MMWR 1998; 47:151-4.
13.- Guay LA, Musoke P, Fleming T, Bagenda D, Allen
M, Nakabito C et al. Intrapartum amnd neonatal single –
dose nevirapine compared with zidovudine for preventionof
mother –to-child tramnsmission of HIV-1 in Kampala,
Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:
14.- Nielsen K. Mother-to child transmission of HIV: the
state of the art. Available form: http://www.medscape.com/
medscape/con/1999/ICAAC/Story.cfm?story_id=832.
15.- Shah MM, Li Y, Christensen RD. Effects of perinatal
zidovudine on hematopoiesis: A comparison of effects on
progenitors from human fetuses versus mothers . AIDS
16.- Culnane M, Fowler Mg, Lee SS, McSherry G, Brady
M, O’Donell K, et al. Lack of long-term effects of in utero
exposure to zidovudine among uninfected children born to
HIV-infected women. JAMA 1999; 281:151-7.
17.- Blanche S, Tardieu M, Rustin P, Slama A, Barret B,
Firtion G, et al. Persistent mitochondrial dysfunction and
perinatal exposure to antiretroviral nucleoside analogues.
Lancet 1999; 354: 1084-9.
Full text